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ATP-insensitive KATP channel mutations cause
neonatal diabetes mellitus (NDM). To explore the
mechanistic etiology, we generated transgenic mice
carrying an ATP-insensitive mutant KATP channel
subunit. Constitutive expression in pancreatic b cells
caused neonatal hyperglycemia and progression to
severe diabetes and growth retardation, with loss of
islet insulin content and b cell architecture. Tamox-
ifen-inducedexpression inadultbcells led todiabetes
within2weeks,withsimilar secondaryconsequences.
Diabetes was prevented by transplantation of normal
islets under the kidney capsule. Moreover, the endog-
enous islets maintained normal insulin content and
secretion in response to sulfonylureas, but not
glucose, consistent with reduced ATP sensitivity of
b cell KATP channels. In NDM, transfer to sulfonylurea
therapy is less effective in older patients. This may
stem from poor glycemic control or lack of insulin
because glibenclamide treatment prior to tamoxifen
induction prevented diabetes and secondary compli-
cations in mice but failed to halt disease progression
after diabetes had developed.
INTRODUCTION
In the pancreatic b cell, ATP-sensitive K+ (KATP) channels play
a critical role in coupling membrane excitability to glucose-
stimulated insulin secretion, thereby maintaining blood glucose
within a narrowphysiologic range. Increase inglucosemetabolism
leads to elevated intracellular [ATP]:[ADP], closure of KATP chan-
nels, and membrane depolarization, inducing voltage-dependent
Ca2+ entry, which, in turn, triggers insulin secretion. Conversely,
decrease in the metabolic signal opens KATP channels and
suppresses the electrical trigger of insulin secretion. Sulfonylurea
drugs, widely used in diabetes treatment, promote insulin secre-
tion by binding to the regulatory sulfonylurea receptor-1 (SUR1)
subunit and inhibiting KATP current, thus inducing insulin secretion
(Ashcroft and Gribble, 1999; Nichols, 2006).
Mutations that result in ‘‘overactive’’ KATP channels should
decrease membrane excitability and impair glucose sensing by140 Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inthe b cell. Reduced insulin secretion and a diabetic phenotype
are predicted, and genetic studies have now identified KATP
channel mutations as the most common cause of neonatal dia-
betes mellitus (NDM) in humans (Gloyn et al., 2004b; Hamilton-
Shield, 2007; Polak and Cave, 2007; Sperling, 2006; Vaxillaire
et al., 2004). Predicting the human disease, we previously
demonstrated that mice constitutively expressing ATP-
insensitive b cell KATP channels develop profound neonatal dia-
betes (Koster et al., 2000). These mice die shortly after birth,
precluding detailed analysis of disease progression. We have
now generated a novel inducible KATP ‘‘gain-of-function’’ trans-
genic mouse by inserting an ATP-insensitive Kir6.2 construct
into the Rosa26 locus under Cre-recombinase control. These
mice permit selective induction of transgene expression in any
tissue of interest, thereby modeling tissue-specific expression
of NDM mutations, when crossed into appropriate Cre-express-
ing mice. By crossing with rat-insulin-promoter-driven Cre-
recombinase-expressing (Rip-Cre) (Herrera, 2002) or tamox-
ifen-inducible Pdx1PBCreER (Pdx-Cre) (Zhang et al., 2005)
mice, we generated pancreatic-specific Rip-Cre/Rosa26-
Kir6.2[K185Q,DN30] double-transgenic (Rip-DTG) or Pdx-Cre/
Rosa26-Kir6.2[K185Q,DN30] double-transgenic (Pdx-DTG)
mice. Rip-DTG and Pdx-DTG mice develop severe glucose intol-
erance around weaning or within 2 weeks after tamoxifen injec-
tion, respectively, and progress to severe diabetes. These mice
survive with unmeasurably high blood sugars through adulthood
but demonstrate growth retardation, profound loss ofbcell mass,
and dramatic reduction of total insulin content. The secondary
progression of the disease is completely avoided by syngeneic
islet transplantation or early onset sulfonylurea therapy. These
results have important implications for understanding human
NDM progression and therapeutic possibilities.
RESULTS
b Cell Expression of ATP-Insensitive Channels
NDM mutations in KATP channels all cause loss of ATP sensitivity,
either by reduced ATP affinity (mutations in the ATP-binding site)
or allosterically by enhancing open probability. By combining an
ATP-binding site mutation (K185Q) with an allosteric gating
mutation (truncation of the N-terminal 30 amino acids, DN30),
we have generated channels with significantly lower ATP sensi-
tivity (Koster et al., 1999b). This Kir6.2[K185Q,DN30] was tar-
geted to the Rosa26 locus in ES cells, using a Neo/WSS cassettec.
Cell Metabolism
Secondary Consequences of NDMthat leads to expression of both the Kir6.2[K185Q,DN30] protein
and GFP via an internal ribosome entry site (IRES) upon
Cre-mediated recombination. Correctly targeted ES cells were
injected into CB20 blastocysts. We obtained several chimeras,
and successful germline transmission was obtained in one line
(Figure 1A). Rosa26-Kir6.2[K185Q,DN30] (Rosa26-Kir6.2) trans-
genic mice were first crossed with rat-insulin-promoter-driven
Cre-recombinase (Rip-Cre) mice in order to drive transgene
expression in b cells. Rip-Cre/Rosa26-Kir6.2[K185Q,DN30]
double-transgenic mice (Rip-DTG) were born at the expected
frequency, and, even though these mice develop a dramatic dia-
betic phenotype over time, neonatal lethality was avoided, with
100% survival into adulthood. Consistent with transgene expres-
sion, b-cell-specific green fluorescence was present in islet cells
from Rip-DTG mice, but not in the three control genotypes (WT,
Rip-Cre, or Rosa26-Kir6.2) (Figure 1B).
Progressive Neonatal Diabetes in Rip-DTG Mice
In contrast to our previous report on constitutively overactive
KATP transgenic mice, no neonatal lethality was seen in RIP-
DTG mice, although blood glucose was consistently > 200 mg/dl
within the first 2 weeks, and there was a progressive elevation
Figure 1. Induced Expression of ATP-Insensitive Kir6.2 Subunits Leads to Development of Severe Diabetes in Rip-DTG Mice
(A) Generation of mice with inducible Kir6.2[K185Q,DN30] expression. The targeting strategy for generation of a Cre-inducible Kir6.2[K185Q,DN30] transgene in
the ROSA26 locus is shown. ES cells were transfected with the depicted vector, and homologous recombinants were detected by Southern blot (data not shown).
Correctly targeted ES cells were injected into blastocysts.
(B) Cre-mediated recombination of the Neo/WSS cassette leads to expression of the Kir6.2[K185Q,DN30] protein but also to expression of a GFP via an internal
ribosome entry site (IRES). Freshly isolated islets from Rip-Cre/Rosa26-Kir6.2[K185Q,DN30] (Rip-DTG) animals show diffuse green fluorescence in the core of the
islet, reflecting transgene expression in b cells.
(C) Fed (solid) and fasted (dashed) blood glucose levels from Rip-DTG and control (WT, Rip-Cre, and Rosa26-Kir6.2[K185Q,DN30] [Rosa-Kir6.2]) littermates over
time. n = 8–10 mice in each group; mean ± SEM.
(D) Fed plasma insulin from all four genotype mice at 20 to 30 days old and 50 to 100 days old. n = 8–10 mice in each group; mean ± SEM.Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc. 141
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Secondary Consequences of NDMFigure 2. Growth Retardation Accompanied by Dramatic Changes in Islet Morphology and Hormone Content in Diabetic Rip-DTG Animals
in Late Stages of Diabetes
(A) (Left) Photographs of Rip-DTG mice and single-transgenic littermates at 21 days and 75 days. (Right) Body weight as a function of age for Rip-DTG, WT,
and single-genotype littermates (n = 12–15 in each case; mean ± SEM).142 Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc.
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Secondary Consequences of NDMFigure 3. Insulin Sensitivity and Secretion
in Rip-DTG and Control Littermate Mice
(A) Intraperitoneal glucose tolerance test on fasted
WT, Rip-DTG, and single-transgenic littermate
mice at 6 weeks of age. Blood [glucose] versus
time following injection of 1.5 g/kg glucose. n = 8–
11 animals in each group; mean ± SEM.
(B and C) Response of fed WT, Rip-DTG, and
single-transgenic littermate mice at 6 weeks of age
to single i.p. injection of glibenclamide (1.0 mg/g)
(B) or response of 6 hr fasted mice to i.p. injection
of insulin (0.5 mU/g) (C). n = 6–10 animals in each
group; mean + SEM.
(D) Insulin content of isolated islets from WT, Rip-
DTG, and single-transgenic littermate mice at
6 weeks of age and Rip-DTG also determined
at 3 months of age (dashed bar, glucose >
600 mg/dl for > 2 months). n = 5–7 animals in
each case; mean ± SEM.
(E) Glucose-dependent insulin secretion from iso-
lated islets as in (D). Batches of ten islets were
statically preincubated with low glucose and
then incubated at different glucose concentra-
tions (with or without glibenclamide and K+)
for 1 hr. Insulin release was measured in the media
by radioimmunoassay. n = 5–7 mice in each
group; samples done in triplicates; mean ± SEM.
Significant differences *p < 0.05 between
test and WT mice (D) or 1 mM glucose (E) are
indicated.of fed and fasted glucose through weaning, reaching immeasur-
able high levels (>600 mg/dl) at around 2 months (Figure 1C).
Concomitant with the developing hyperglycemia, plasma insulin
levels were decreased at early stages and dropped close to the
level of detection (0.18 ng/ml) at late stages (Figure 1D). Impor-
tantly, none of these symptoms were present in control litter-
mates (Figure 1), indicating no aberrant expression of the
Rosa26-Kir6.2[K185Q,DN30] or detrimental effects of RIP-Cre
expression. Neonatal Rip-DTG mice had normal body weight.
However, significant growth retardation accompanied the
subsequent progression of the disease (50% reduction in
body weight compared with control littermates by about
3 months, paralleled by similar reduction in pancreatic weight,
such that pancreatic weight/body weight ratio remained normal)
(Figure 2A and data not shown). However, the insulin content of
the pancreas and the islet mass dropped precipitously over this
time (to less than 10%) in Rip-DTG mice, with no changes in
control littermates (Figure 2B).
Immunohistochemical analyses were performed on sectioned
pancreata. Low-magnification images of hematoxylin-and-
eosin-stained sections indicate a reduced number of islets per
pancreas in Rip-DTG (by 50% in moderate to > 90% in severe
diabetic mice) (Figure 2B). High-magnification images (Figure 2C)
suggest a reduced islet size with time, although islet integrity is
maintained. Immunostaining for insulin and glucagon confirms
relatively normal distribution of both insulin-containing b cells
and glucagon-containingacells in early stages of the disease (Fig-
ure 2C, upper panels). However, a cell infiltration, evidenced by
glucagon staining in the core of the islet, together with reduced
insulin immunofluorescence was observed in later stages of the
disease, and, at the latest stages (glucose > 600 mg/dl for > 3
weeks), both insulin and glucagon staining essentially disappears
(Figure 2C, middle and lower panels).
Consistent with the elevated blood glucose levels, Rip-DTG
animals more than 6 weeks old showed impaired, but not
completely absent, responses to glucose and glibenclamide
injection (Figures 3A and 3B), although direct comparison to litter-
mate controls is difficult, given the elevated glucose baselines.
Similarly, insulin sensitivity is not readily comparable between
Rip-DTG and other genotypes, but dramatic glucose lowering
was observed in response to insulin in Rip-DTG animals (Fig-
ure 3C). These mice reiterate a profound diabetes, but the time
course is slower than that which we observed with constitutive
Rip expression (Koster et al., 2000), potentially a result of incom-
plete expression of the transgenes or, perhaps, slow induction of
the Cre-lox system.
(B) (Top) Low-magnification (203) pancreatic sections from Rip-DTG and control animals stained with hematoxylin-eosin and (lower) pancreatic insulin content at
75 days for Rip-DTG, WT, and single-genotype littermates. n = 4–8 mice in each case; mean ± SEM.
(C) Hematoxylin and eosin staining (left), insulin (middle), and glucagon (right) immunostaining of pancreatic sections from WT control (top) and Rip-DTG mice at
early (middle) and late stages of disease (bottom).Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc. 143
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Secondary Consequences of NDMFigure 4. Rapid Development of Severe Diabetes in Tamoxifen-Induced Pdx-DTG Mice and Complete Rescue by Syngeneic Transplant
of Normal Islets
(A) Fed blood glucose levels from Pdx-DTG and control (WT, Pdx-Cre, and Rosa-Kir6.2) littermate mice following onset of tamoxifen induction (at 6 weeks of age;
n = 6–8 mice in each group; mean ± SEM). Transplantation of 300 syngeneic islets from single-transgene or control littermates was performed in a subset of
Pdx-DTG animals (n = 5, black squares) 2 days before the onset of tamoxifen induction.
(B) Blood glucose and plasma insulin levels in fed Pdx-DTG (transplanted and nontransplanted as indicated) and control littermate mice 3 weeks following tamox-
ifen induction. n = 5–8 mice in each group; mean ± SEM.144 Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc.
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Secondary Consequences of NDMGlucose-Dependent Insulin Secretion Is Lost
in Rip-DTG Mice
Consistent with the overt diabetes and drastic loss of pancreatic
insulin content and islet insulin staining in adult Rip-DTG mice,
measured insulin content was negligible in isolated RIP-DTG
islets from animals with blood glucose > 600 mg/dl (Figure 3D),
and there was negligible insulin secretion from these islets in
response to glucose, glibenclamide, or KCl (Figure 3E). How-
ever, insulin content of islets isolated from animals with blood
glucose between 400 and 600 mg/dl was still 60% of control
(Figure 3D). Glucose-dependent secretion from these islets
was negligible, as predicted for the expected KATP overactivity,
but there was a significant response to glibenclamide, and
release in response to K+ depolarization was essentially normal,
indicating no impairment of secretory process downstream of
the electrical signal at this stage (Figure 3E).
Induction of ROSA-Kir6.2 in Adults
The above results demonstrate that Rip-Cre-induced expression
of the Kir6.2[K185Q,DN30] transgene reiterates the expected
primary consequences of ATP-insensitive KATP channels but
also shows that this secondarily leads to a dramatic loss of
insulin content and a lack of response to sulfonylureas, which
is not naively predicted. In patients with NDM, it has been
observed that the ability to transfer to sulfonylurea therapy is
greater when the transfer is attempted at a young age (Pearson
et al., 2006) and that older adults, even with relatively less severe
mutations, cannot always transfer (e.g., Masia et al., 2007). The
profound secondary loss of insulin content that we observe in
Rip-DTG animals underlies a gradual loss of glibenclamide-
sensitive secretion (Figure 3E), leading us to suggest that the
same secondary progression may contribute to the failure to
transfer to sulfonylureas in older adults (see below).
What is the cause of the secondary loss of insulin content?
‘‘Glucotoxicity,’’ as a result of the profound systemic hypergly-
cemia or low circulating insulin levels, is the likely mechanism,
leading to death of b cells (Poitout and Robertson, 2002). We
thus hypothesize that maintenance of normoglycemia/normal
insulin levels might protect against this secondary consequence.
One way to test this is to transplant healthy normal islets into the
transgenic animals prior to the development of diabetes.
However, this is not a trivial procedure in neonatal animals, and
we have, therefore, utilized a second induction system that
permits temporal control of the onset of transgene induction.
Tamoxifen-inducible Pdx-Cre mice were crossed with Rosa26-
Kir6.2[K185Q,DN30] transgenic mice, resulting in animals in
which the transgene was expected to be activated in Pdx-ex-
pressing islet cells, only following tamoxifen injection. As shown
in Figure 4, noninjected Pdx-Cre/Rosa26-Kir6.2[K185Q,DN30]
double-transgenic (Pdx-DTG) mice maintained normal blood
glucose as adults, as well as normal glucose tolerance (dataCenot shown). To induce expression, we injected Pdx-DTG and
littermate control mice daily with tamoxifen (50 mg/g body weight)
for 5 days. Within 2 days of the onset of injections, blood glucose
began to rise and reached immeasurable levels in 2 weeks in
Pdx-DTG animals, with no effects on single-transgenic or wild-
type littermates (Figure 4A). Thus, the NDM disease phenotype
can be readily induced in adulthood, following transgene induc-
tion. Moreover, the secondary consequences appear to be as
severe as when the disease is initiated in the neonatal period
since, as shown in Figure 4D, islet insulin content essentially
disappears in Pdx-DTG within 3 weeks of tamoxifen induction.
Maintenance of Normoglycemia Prevents Secondary
Consequences of NDM
In order to test whether it is the chronic hyperglycemia/hypoinsu-
linemia that leads to the b cell loss in DTG animals, we attempted
to maintain normoglycemia by transplanting Pdx-DTG mice with
300 syngeneic islets under the kidney capsule 2 days prior to
onset of tamoxifen induction (Montana et al., 1993). As shown
in Figure 4, this resulted in a dramatic avoidance of diabetes,
and transplanted mice maintained normoglycemia and near
normal plasma insulin levels for the ensuing 3 weeks (Figures 4A
and 4B), at which point the animals were sacrificed and islets
were isolated. Just prior to termination, glucose tolerance tests
were performed (Figure 4C). Transplanted Pdx-DTG animals
showed mild glucose intolerance but still returned to basal
glucose within 2 hr.
Most significantly, the endogenous islets from transplanted
animals failed to develop any of the secondary morphological
changes or loss of insulin content. By 3 weeks following induc-
tion, islet insulin content was essentially normal, as was a and
b cell distribution within the islets (Figure 4D). Consistent with
the drastic loss of insulin content in Rip-DTG animals, there
was negligible insulin secretion from nontransplanted, tamox-
ifen-induced Pdx-DTG islets (Figure 4E). In endogenous islets
from transplanted Pdx-DTG mice, there was also no glucose-
stimulated insulin secretion, as expected. However, these islets
retained essentially normal secretion in response to K+ depolar-
ization and significant release in response to the sulfonylurea
glibenclamide (Figure 4E). Thus, it appears that maintenance of
normoglycemia does, indeed, lead to avoidance of all secondary
consequences of the diabetes. As discussed below, these find-
ings have implications for the progress of human NDM and
for the potential benefits of maintaining good glycemic control
through early sulfonylurea intervention.
Sulfonylurea Treatment Prevents Secondary
Consequences
It is now clear that sulfonylurea drugs can effectively trigger
insulin secretion in NDM patients, even after long-standing
disease, although it is also the general finding that dose(C) Intraperitoneal glucose tolerance test on Pdx-DTG (black squares, transplanted; white squares, nontransplanted) and control littermate mice. Blood [glucose]
versus time following injection of 1.5 g/kg glucose. n = 4–5 animals in each group; mean ± SEM.
(D) Intrinsic GFP fluorescence of representative freshly isolated islets (left), as well as insulin (middle) and glucagon (right) immunostaining of pancreatic paraffin
sections from WT (top) and from transplanted and nontransplanted Pdx-DTG mice at 3 weeks following induction (below).
(E) Glucose-dependent insulin secretion from isolated islets. Batches of ten islets were statically preincubated with low glucose and then incubated at different
glucose concentrations (with or without glibenclamide or K+) for 1 hr. Released insulin was measured by radioimmunoassay. n = 4–7 mice in each group; samples
done in triplicates; mean ± SEM. Significant differences *p < 0.05 between test and 1 mM glucose control are indicated.ll Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc. 145
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Secondary Consequences of NDMFigure 5. Rescue of Diabetes and Its
Secondary Consequences in Pdx-DTG
Mice Treated with Sulfonylureas
(A) Fed blood glucose levels from Pdx-DTG
treated with glibenclamide pre- and posttamoxi-
fen induction with respect to controls (WT- gli-
benclamide-treated and Pdx-DTG-untreated
mice). At 6 weeks of age, Pdx-DTG mice were
implanted with slow-release glibenclamide
pellets 1 day before (black diamonds) or
following onset of tamoxifen induction (gray
diamonds) (n = 4 mice in each group; mean ±
SEM). Dashed line shows response of WT mice
to glibenclamide implantation (from Remedi and
Nichols, 2008).
(B) Glucose-dependent glucagon secretion from
isolated islets as in (A). Batches of ten islets
were statically incubated at different glucose
concentrations for 1 hr. Glucagon release was
measured in the media by radioimmunoassay
(n = 3 mice in each group; samples done in trip-
licates; mean ± SEM). Significant differences *p <
0.05 between test and same glucose concentra-
tion from controls are indicated.
(C) Glucose-dependent insulin secretion from
isolated islets. Batches of ten islets were stati-
cally preincubated with low glucose and then
incubated at different glucose concentrations
(with or without glibenclamide or K+) for 1 hr
(n = 3 mice in each group; samples done in trip-
licates, in Pdx-DTG animals implanted with gli-
benclamide pellets before [pre-] or after [post-]
induction or in control littermates; mean ±
SEM). Released insulin was measured by radio-
immunoassay. Significant differences *p < 0.01
between test and 1 mM glucose control are
indicated.requirements tend to increase with length of disease and that, in
some cases, sulfonylurea therapy is ineffective. Therefore, we
asked whether sulfonylurea therapy can protect these mice
from hyperglycemia and the secondary consequences of dia-
betes. To achieve chronic dosing of sulfonylureas, we implanted
adult Pdx-DTG mice with slow-release glibenclamide pellets
under the skin (Remedi and Nichols, 2008) 2 days before onset
or 6 days after cessation of tamoxifen induction. In Pdx-DTG
mice treated with glibenclamide before tamoxifen induction,
fed glucose and islet insulin content remained essentially normal
at 60 days postinduction (Figure 5). These results dramatically
illustrate the effectiveness of sulfonylureas to trigger release of
endogenous insulin and protect against secondary conse-
quences of the diabetes. Moreover, isolated islets from these
mice show normal responses to K+ depolarization and to gliben-
clamide but do not respond to glucose, exactly as expected
(Figure 5C). Critically, however, glibenclamide treatment was inef-
fective when initiated following the development of diabetes
(glucose 400 mg/dl); blood glucose continued to rise to above
600 mg/dl (Figure 5A), and, at 60 days, insulin content was signif-146 Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inicantly reduced (Figure 5B) and insulin release was substantially
reduced (Figure 5C). It is important to note that glucose had
already risen to quite high (400 mg/dl) levels at pellet implanta-
tion in the latter animals, but, as discussed below, the finding that
glibenclamide therapy is ineffective at this stage may have impor-
tant implications for the therapeutic outcome in NDM patients
with long-standing or poorly controlled disease.
Reduced ATP Sensitivity of KATP Currents in Pdx-DTG
b Cell Membranes
In recombinant expression, Kir6.2[K185Q,DN30] mutant chan-
nels show marked (100-fold) reduction of ATP sensitivity
(Koster et al., 1999b). In all NDM-associated Kir6.2 mutations,
the underlying molecular phenotype is also reduction of ATP
sensitivity of expressed channels, although loss of ATP sensi-
tivity has not been demonstrated in NDM b cells. In the disease
case, the mutation is heterozygous (as are the DTG mice), so
the expected channel phenotype in b cells should be generated
by mixed expression with wild-type subunits, which typically
results in much weaker shifts in ATP sensitivity (Gloyn et al.,c.
Cell Metabolism
Secondary Consequences of NDM2004b). Consistent with this, endogenous b cell KATP channels
isolated from nondiabetic transplanted Pdx-DTG adult mice
displayed a mild but significant decrease in ATP sensitivity rela-
tive to channels from control littermate membranes (Figures 6A
and 6C). Importantly, there is higher activity in the millimolar
ATP range, consistent with a causal basis for the observed
disease. It is noteworthy that the overall KATP density is not
different in the double-transgenic b cells (Figure 6B), excluding
gross overexpression of KATP subunits as an artifactual basis
for the diabetes in nontransplanted animals and implicating
the critical effect of reduced ATP sensitivity in the disease
mechanism.
Glucagon Secretion and Content Are Lost in Severely
Diabetic Mice
Both Rip- and Pdx-1-driven transgenes should be expressed
primarily in b cells of the adult mice, but it is possible that either
aberrant expression in a cells or lack of paracrine effects of insulin
secretion on a cell function could affect glucagon content and
release in these animals. To examine this, we determined
glucagon levels, as well as islet glucagon content and glucose-
dependent glucagon release. In early stages of disease, Rip-
DTG mice showed a significant increase in plasma glucagon
and enhanced glucagon release at higher glucose levels, possibly
due to the lack of inhibitory effect of insulin on a cells, or enhanced
glucagon content in isolated islets (Figures 7A and 2C). How-
ever, at late stages of the disease, plasma glucagon, as well
as islet glucagon content and release, were undetectable (Fig-
ure 7A), consistent with the absence of glucagon staining
in isolated islets from severely diabetic mice (Figure 2C). Impor-
tantly, endogenous islets from transplanted Pdx-DTG animals
show essentially normal glucagon content and release (Figure 7).
Figure 6. Reduced ATP Sensitivity but
Normal Density of KATP Currents in Primary
b cells from Transplanted Pdx-DTG Animals
(A) Representative currents recorded from inside-
out membrane patches from WT and Pdx-DTG
pancreatic b cells at 50 mV in K-INT solution
(see Experimental Procedures). Membrane
patches were exposed to different ATP concentra-
tions as shown.
(B and C) (B) KATP channel density and (C)
steady-state dependence of membrane current
on [ATP] relative to current in zero ATP (Irel) for
KATP channels from wild-type and Pdx-DTG
b cells. Data points represent means ± SEM;
n = 3 animals (15–30 patches for each genotype).
The fitted lines in (C) correspond to least squares
fits of the Hill equation, with the H (Hill coefficient)
and K1/2 values allowed to vary. For WT, H = 2
and K1/2 = 6 mM (dashed line); for Pdx-Cre/
Rosa-DTG, H = 1.2 and K1/2 = 8 mM (solid line).
Significant differences *p < 0.05 and **p < 0.01
from transgenic with respect to control cells.
This is consistent with the profound
loss of a cells in the untreated Rip-DTG
islets being due to hyperglycemia/hypoin-
sulinemia and further confirms that main-
tenance of normoglycemia does, indeed, lead to avoidance of all
secondary consequences of diabetes, including pancreatic
a cell loss.
DISCUSSION
Physiological Overactivity of KATP Channels
as Cause of NDM
Closure of KATP in response to glucose metabolism couples
membrane excitability to b cell insulin secretion. KATP mutations
that cause loss of ATP sensitivity are, thus, expected to maintain
the membrane in a hyperpolarized state with hyposecretion of
insulin. We previously generated transgenic mice constitutively
expressing mutant KATP channels with reduced ATP sensitivity
under rat insulin promoter control (Koster et al., 2000). These
mice were profoundly diabetic, with marked reduction in serum
insulin levels and dramatic elevation of blood glucose and ketone
(D-3-hydroxybutyrate) levels as neonates, and essentially all
mice died within the first week (Koster et al., 2000). These mice
predicted subsequent genetic studies that demonstrate that
similar mutations, located throughout both the pore-forming
Kir6.2 subunit and the regulatory SUR1 subunit of the KATP
channel, underlie permanent and transient neonatal diabetes
mellitus (NDM) in humans (Gloyn et al., 2004a, 2004b, 2005; Hat-
tersley and Ashcroft, 2005; Massa et al., 2005; Sagen et al.,
2004; Vaxillaire et al., 2004). In all cases, the identified mutations
cause a loss of ATP sensitivity of recombinant KATP channels and
are predicted to cause reduced excitability of the b cell and,
hence, inhibition of insulin secretion in vivo (Gloyn et al.,
2004b; Koster et al., 2005, 2007; Masia et al., 2007; Proks
et al., 2005, 2006; Tammaro et al., 2006). This realization has
led to dramatic changes in therapeutic options, and manyCell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc. 147
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Secondary Consequences of NDMFigure 7. Glucagon Content and Secretion
in Rip-DTG Diabetic Mice
(A) Plasma glucagon and glucagon content per
islet from WT, Rip-DTG, and syngenically trans-
planted Pdx-DTG mice determined at3.5 months
of age (n = 3 animals in each case; mean ± SEM).
Plasma glucagon and glucagon content were
determined by radioimmunoassay (see Experi-
mental Procedures). Significant differences *p <
0.05 between test and WT are indicated.
(B) Glucose-dependent glucagon secretion from
isolated islets as in (A). Batches of ten islets were
statically incubated at different glucose concentra-
tions for 1 hr. Glucagon release was measured in
the media by radioimmunoassay (n = 3 mice in
each group; samples done in triplicates). Signifi-
cant differences *p < 0.05 between test and same
glucose concentration from controls are indicated.patients have now successfully transferred from injected insulin
therapy to sulfonylurea tablets (Gloyn et al., 2006; Hattersley and
Ashcroft, 2005; Koster et al., 2007; Masia et al., 2007; Pearson
et al., 2006). Sulfonylurea sensitivity of channel activity also
tends to be mechanistically coupled to ATP sensitivity (Koster
et al., 1999a; Reimann et al., 1999), such that many of these
disease mutations also reduce channel sensitivity to sulfonyl-
ureas (Koster et al., 2005). This may contribute to the generally
observed requirements for high doses of sulfonylureas in treat-
ment of NDM patients (Hattersley and Ashcroft, 2005).
KATP Channel Overactive Mice as a Model
of Human NDM
However, successful transfer from insulin to sulfonylureas has
not proven possible in all cases; generally, transferability seems
negatively correlated with the patient age (Hattersley and Ash-
croft, 2005; Hattersley and Pearson, 2006), and there are several
examples of successful transfer of an infant, but not of the parent
afflicted with the same mutation (Pearson et al., 2006). This might
suggest that secondary loss of insulin availability is a problem
over the course of the disease. In order to assess islet function
in isolation and to assess long-term consequences and mecha-
nisms of NDM, suitable animal models are required. The consti-
tutively expressing ATP-insensitive Kir6.2 transgenic animals
that we first generated (Koster et al., 2000) reiterate essential
features of human NDM, but neonatal death precluded detailed
study. In order to overcome this limitation, we have developed an
inducible model utilizing a Cre induction strategy. The Rosa26-
Kir6.2[K185Q,DN30] transgene incorporates two mutations
that result in significant loss of ATP sensitivity both by disruption
of the ATP-binding site (K185Q) and by increase in intrinsic open
state stability (DN30) (Koster et al., 1999b) and, thus, reiterates
essential features of NDM mutations in recombinant channels.
Blood sugar is elevated within the first few days of life in Rip-
DTG mice (Figure 1), but, contrary to our previous constitutive
KATP channel transgenic mice, glucose does not become
immeasurably high until after weaning, and neonatal death is
avoided (Figures 1C and 1D). Consistent with the subsequent
progression from mild to marked hyperglycemia, serum insulin
levels decrease over time and are undetectable after2 months,148 Cell Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inby which time the mice show significant growth retardation. At
this stage, the animals are profoundly intolerant to glucose and
glibenclamide injections, although blood glucose lowering is still
observed in response to insulin injections, suggesting that insulin
sensitivity is still normal. Pdx-DTG mice remain essentially
normal through adulthood unless the transgene is induced by
tamoxifen injection. Following tamoxifen induction, there is an
accelerated but otherwise identical development of diabetes to
that seen in Rip-DTG, with glucose beginning to rise within
2 days and becoming immeasurable by 2 weeks (Figure 4).
The similar progression of the disease with two distinct activator
transgenes is an important control and argues against any aber-
rant effects of the Rip-Cre or Pdx-Cre expression per se.
Morphologically, isolated islets appear essentially normal at
early stages of the disease in both Rip-Cre and Pdx-Cre mice
(Figure 2C), with normal distribution of insulin and glucagon.
However, dramatic changes are seen as the disease progresses,
with drastic loss of islet cells and a reduced number of islets per
pancreas (assessed by immunocytochemistry) in both DTG
models (Figures 2C and 4D). At these late stages, whole-body
growth retardation is evident, with parallel reduction of pancre-
atic weight, suggesting an overall growth inhibition as a result
of the profound insulinopenia. Isolated islets from both DTG
animals showed dramatic loss of insulin content and failed to
secrete insulin in response to glucose, glibenclamide, or K+
depolarization (Figures 3 and 4). Notably, however, islets iso-
lated from Rip-DTG mice did respond to high K+ depolarization
at early stages of the disease, reflecting maintained insulin
content (Figure 3) and indicating that the insulin secretory
machinery, downstream of the electrical signal, is intact at this
stage.
An unanticipated finding of the present study was that
glucagon content initially increases in diseased islets and subse-
quently falls to undetectable levels, with concomitant changes in
glucagon secretion and blood levels (Figure 7). Relevant data
from NDM patients are not available, although type 2 diabetic
patients can show hyperglucagonemia and type 1 patients can
progress to lack-of-glucagon response to hypoglycemia (Bansal
and Wang, 2008; Brown et al., 2008; Del Prato and Marchetti,
2004). At this juncture, we can only speculate as to likelyc.
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quence of a lack of inhibitory effects of paracrine secretion of
insulin (Bansal and Wang, 2008; Rorsman et al., 2008), but, at
later stages, islet death resulting from systemic hyperglycemia/
hypoinsulinism leads to loss of both insulin-containing b cells
and glucagon-containing a cells.
Maintenance of Normoglycemia Prevents Secondary
Complications
Mechanistically, the secondary loss of islet cells could be the
result of an intrinsic process, potentially a result of chronic hyper-
polarization and low intracellular [Ca2+], or it could result from the
systemic hyperglycemia/lack of insulin that is present. By trans-
planting syngeneic islets into the kidney capsule prior to tamox-
ifen induction in Pdx-DTG animals, we have demonstrated that
the latter explanation is correct (Figure 4). Even though the trans-
gene is expressed at a high level (indicated by GFP fluores-
cence), these animals are completely spared from diabetes
(which, incidentally, seems to rule out a paracrine mechanism
by which the diseased islets secrete an agent that acts extracel-
lularly to kill b cells) and maintain normal islet morphology and
insulin content over the time course that would otherwise lead
to complete loss of insulin content (Figure 5B). In these animals,
the diseased endogenous islets retain normal insulin secretion in
response to K+ depolarization and near normal response to gli-
benclamide (Figure 5B), yet glucose-dependent secretion is
essentially absent, consistent with the expected consequences
of ATP insensitivity of KATP channels. Because islet viability is
unaffected in these mice, we were able to assess the functional
properties of endogenous b cell KATP channels. Consistent with
mixed expression of transgenic and wild-type subunits, b cell
KATP channel density was essentially normal, but there was
a significant reduction of ATP sensitivity (Figure 6). By increasing
KATP activity at any given glucose concentration, this will corre-
spondingly inhibit secretion in response to glucose, but not in
response to K+ or glibenclamide.
The transplantation results clearly show that secondary loss of
insulin content and secretion is a consequence of systemic dia-
betes. Patients with NDM typically present with extremely high
glucose levels, and glucose control on insulin therapy is, subse-
quently, frequently poor. We speculate that exposure to episodic
hyperglycemia may lead to similar secondary progression in
human NDM patients as we observe in DTG mice. Such
a progression may underlie the finding that the ability to transfer
to sulfonylureas (i.e., to trigger endogenous insulin secretion)
declines with duration of the disease (Pearson et al., 2006).
This is further supported by the clear demonstration that early
sulfonylurea intervention in the Pdx-DTG mice can completely
prevent diabetes and secondary complications following subse-
quent tamoxifen induction, whereas glibenclamide is ineffectual
once the disease has developed and insulin content has been
lost (Figure 5).
EXPERIMENTAL PROCEDURES
Generation of Rosa26-Kir6.2[K185Q,DN30] Mice
Figure 1 shows the targeting strategy that we used for generation of a Cre-
inducible Kir6.2[K185Q,DN30] transgene (Koster et al., 2000) in the Rosa26
locus. ES cells were transfected with the depicted vector, and homologousCerecombinants were detected by Southern blot. Correctly targeted ES cells
were injected into blastocysts. We obtained several chimeras, and successful
germline transmission into offspring was confirmed by PCR. Note that
Cre-mediated recombination of the Neo/WSS cassette leads to expression
of the Kir6.2[K185Q,DN30] protein but also to expression of a GFP via an
internal ribosome entry site (IRES); therefore, GFP can be used to detect
successful recombination.
We generated a Rosa26 locus targeting vector in which CAG promoter-
driven expression of the Kir6.2[K185Q,DN30] mutant and IRES-GFP is pre-
vented by a loxP-flanked Stop cassette. This vector was transfected into
V6.5 ES cells that were screened for correct integration by standard Southern
blot methods. Correctly targeted ES cells were used to generate chimeras,
which were backcrossed to C57/Bl6 background and examined for germline
transmission. All Rosa26-Kir6.2[K185Q,DN30] mice were heterozygous for
the Kir6.2[K185Q,DN30] transgene.
Blood Glucose and Plasma Insulin and Glucagon
All experiments were performed in compliance with the relevant laws and insti-
tutional guidelines and were approved by the Washington University Animal
Studies Committee. Tail blood in fed/fasting conditions was assayed for
glucose content using the Glucometer Elite XL described above. Plasma
insulin and glucagon were measured using a rat insulin enzyme-linked immu-
noabsorbent assay kit (ELISA Kit) and glucagon radioimmunoassay (RIA),
respectively.
Glucose and Insulin Tolerance Tests
Intraperitoneal glucose tolerance test was performed in 12 hr fasted mice by
injection of a bolus of glucose (1.5 g/kg body weight). For insulin tolerance
test, mice were injected with 0.5 U insulin/kg body weight following a 5 hr
fast. Blood was taken at different times (indicated in figures) and assayed for
glucose content as above.
Glibenclamide Sensitivity Test
Mice were intraperitoneally injected with glibenclamide (30 mg/kg body
weight). Only double-transgenic mice (diabetic) were also injected with higher
doses of glibenclamide (100 and 400 mg/kg body weight). Blood was taken at
different times and assayed for glucose content as above.
Total Insulin Content per Pancreas
Whole pancreas was removed and disrupted in homogenization buffer
containing a mixture of protease, phosphatase, and kinase inhibitors using
a Polytron homogenizer. Samples were centrifuged at low speed, and super-
natants were used to measure insulin content. Rat insulin radioimmunoassay
according to manufacturer’s procedure (Linco Inc., St. Charles, MO) was
used to determine the total insulin content per pancreas.
Islet Isolation
Mice were anesthetized with halothane (0.2 ml) and killed by cervical disloca-
tion. The bile duct was cannulated and perfused with Hank’s balanced salt
solution (Sigma Corp., St. Louis, MO) containing collagenase (0.3 mg/ml,
Collagenase Type XI, Sigma Corp., St. Louis, MO). Pancreata were removed
and digested for 5 min at 37C, hand shaken, and washed three times
in cold Hank’s solution. Islets were isolated by hand under a dissecting
microscope, and pooled islets were maintained in CMRL-1066 culture medium
(GIBCO)supplemented with fetal calf serum (FCS,10%), penicillin (100units/ml),
and streptomycin (100 mg/ml).
Insulin and Glucagon Release
Following overnight incubation in low-glucose (5.6 mM) CMRL-1066 medium,
islets (10 per well in 12-well plates) were preincubated in glucose-free CMRL-
1066 plus 3 mM glucose (only for insulin secretion) and then incubated for
60 min at 37C in CMRL-1066 plus different (glucose), 1 mM glibenclamide,
or 30 mM KCl, as indicated. After the incubation period, the medium was
removed and assayed for insulin or glucagon release. Islets were disrupted
using ethanol-HCl extraction and sonicated on ice prior to estimation of insulin
and glucagon content. Experiments were repeated in triplicate. Insulin and
glucagon secretion and content were measured by RIA, as above.ll Metabolism 9, 140–151, February 4, 2009 ª2009 Elsevier Inc. 149
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Pancreata were fixed in 10% formalin and paraffin embedded for serial
sectioning (5 mm thick). Hematoxylin and eosin staining was carried out as
described previously (Remedi et al., 2004). For immunofluorescence, pancre-
atic sections were incubated overnight at 37C with guinea pig anti-insulin
primary antibody or guinea pig anti-glucagon primary antibody (1:250 or
1:500, respectively; Linco Research, St. Charles, MO). Primary antibodies
were detected by incubating for 1.5 hr at 25C with anti-guinea pig secondary
antibody conjugated with the Alexa 488 fluorescent dye (Molecular Probes,
Eugene, OR) (Remedi et al., 2004).
Islet Transplantation
We followed protocols developed by Dr. Bonner-Weir and colleagues (Mon-
tana et al., 1993) to transplant islets isolated from anesthetized mice as above
under the kidney capsule of recipients on the day of isolation. Briefly, islets
were aspirated into the tip of a Hamilton syringe (Fisher Inc.) and then injected
into a plastic transplant tubing attachment with a beveled cut end. Recipient
mice were anesthetized with Avertin (0.25 mg/g mouse body weight) and
opened just above the kidney. The kidney was exposed, and a small incision
was made in the kidney capsule using a 23 g needle. The tip of the transplant
tubing was inserted under the capsule, and 300 islets per transplant were im-
planted. The tubing was removed, the opening in the capsule was cauterized,
and the animal was sutured and allowed to recover.
Chronic Sulfonylurea Treatment
Glibenclamide (Glyburide) pellets at the concentration of 2.5 mg per 60 day
release were obtained from Innovative Research of America (Sarasota, FL).
Six-week-old mice were anesthetized with Avertin (0.25 mg/g mouse body
weight). The skin on the lateral side of the neck of the animal was lifted,
and pellets were implanted under the skin of the neck using a stainless steel
precision trochar.
Analysis of KATP Channel Activity
Patch-clamp experiments of dispersed pancreatic b cells were made at room
temperature in a chamber that allowed rapid exchange of bathing solution. The
pipette (extracellular) and bath (cytoplasmic) solution (Kint) used in excised
patch experiments had the following composition: 140 mM KCl, 1 mM
EGTA, and 10 mM HEPES (pH 7.3) (all chemicals purchased from Sigma-
Aldrich, St. Louis, MO). ATP (dipotassium salt) was stored as a 100 mM stock
in Kint solution, with the pH adjusted to 7.3. Stocks were stored at 20C and
diluted into working concentrations on each experimental day. Currents were
recorded from excised membrane patches at a holding potential of 50 mV,
filtered at 1 kHz, digitized at 5 kHz, and stored directly on a computer hard
drive using Clampex v.9 software (Molecular Devices, Sunnyvale, CA). The
ATP dose response was quantified by fitting the raw data with a Hill equation:
Irel = 1=

1+
½ATP=K1=2;ATP
H
(Equation 1)
in which Irel is the current relative to that in the absence of ATP, [ATP] is the ATP
concentration, K1/2,ATP is the half-maximal inhibitory ATP concentration, andH
is the Hill coefficient.
Statistics
Data are presented as mean ± SEM. Differences among the four genotypes
were tested using analysis of variance (ANOVA) and post hoc Duncan’s test.
When only two groups were compared, unpaired t tests were used to assess
significance. Differences were assumed to be significant in each case if p <
0.05, unless indicated; nonsignificant differences are not indicated.
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